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Sumnlary 
The CD45RA and CD45RO isoforms of the leukocyte common antigen identify functionally 
distinct "naive" and "memory" T cell subsets. While antigenic and mitogenic stimuli are known 
to initiate  transition  from the naive to memory state,  little is known  about the role of cyto- 
kines in this process. This report demonstrates that in vitro exposure of purified CD45RA+/ 
CD45RO-  peripheral  blood  lymphocytes  (PBL)  to  interleukin  2  (IL-2)  promotes  their 
conversion to the CD45RA-/CD45RO + phenotype. Conversion to CD45RO occurs for both 
the CD3 + and CD3-/CD56 + lymphocyte subsets, but occurs more rapidly, and at lower IL-2 
concentrations,  in the CD3-/CD56 + population.  Expression of CD45RO was observed only 
in response to IL-2 and was not observed during long-term culture in IL-4, IL-6, or IL-7. We 
also examined the effect of IL-2 on the expression of adhesion molecules by T cells. The expression 
of CD2, CD11a, and CDw29 increased, and expression of Leu-8 (LAM-1) decreased, on cultured 
CD45RA+/CD45RO -  cells  after  they  converted  to  expression  of CD45RO.  In  contrast, 
lymphocytes that remained  CD45RA +/CD45RO-  after 10 d in culture exhibited no change 
from their baseline adhesion molecule profile.  Finally,  to test the role of endogenous IL-2 during 
T  cell activation we stimulated CD45RA+/CD45RO -  PBL with immobilized  anti-CD3  in 
the presence of neutralizing  anti-IL-2 antibody and/or cyclosporin A. Both agents significantly 
reduced the expression of CD45RO and the effect of cyclosporin A was reversed by exogenous 
IL-2. We conclude that IL-2 promotes CD45RA + cells to express the memory phenotype and 
is a mediator  of CD45RO  expression after stimulation  of the T  cell receptor/CD3  complex. 
T 
he leukocyte common antigens (CD45) are a family of 
180--220-kD transmembrane glycoproteins present in high 
abundance on the surface of all leukocytes (1).  They share 
a common intracellular domain that exhibits protein tyrosine 
phosphatase activity (2). Their different extracellular  domains 
are produced through alternate mRNA splicing of three exons 
(A, B, C) present on a common parent  gene (1, 3). While 
the exact function and role of the different CD45 proteins 
remains to be determined, the CD45RA (RA, 1 identified by 
mAb Leu-18) and CD45RO (RO, identified by mAb UCHL1) 
isoforms have proven to be reliable markers for identifying 
functionally distinct "naive" and "memory" T  cell subsets 
(4-7).  T  cells  that  express the RA+/RO -  phenotype  are 
small, resting lymphocytes that  secrete a limited repertoire 
of cytokines (5, 8, 9); that express low levels of specific adhe- 
sion molecules (5,  10,  11); and that respond slowly and al- 
most exclusively to primary antigenic stimuli (7, 12, 13). This 
1 Abbreviations used in thispaper: CM, complete  medium; CsA, cyclosporin 
A; R.A, CD45RA; KO, CD45RO; TIL, tumor-infiltrating lymphocytes. 
phenotype predominates in peripheral blood, especially in the 
blood of neonates (14). In contrast,  T  cells that express the 
RA-/RO + phenotype are larger,  more activated lympho- 
cytes that express activation markers such as CD25; that secrete 
a large repertoire of cytokines including IL-2, IL-4, IL-5, IL-6, 
GM-CSF, TNF, and IFN-3q that express high levels of adhe- 
sion molecules including CD2, LFA-1, and CDw29; and that 
respond briskly to recall antigens  (4-13).  CD45RO + lym- 
phocytes predominate at sites of inflammation  (15),  within 
mucosal tissues (16, 17), and among the population of tumor- 
infiltrating  lymphocytes (TIL)  (18,  19). 
Antigen presentation is believed to be the primary in situ 
signal  that  induces  RA +/RO-  lymphocytes to  transform 
into memory cells and concordantly express the R.O isoform. 
Several in vitro models have been developed to study this tran- 
sition  process including  activation  of R_A +/RO-  T  cells 
with alloantigen (13) or with mitogens such as Con A, PHA, 
or anti-CD3 mAb (10, 13, 20). However, little is known about 
the role of specific cytokines in the phenotypic conversion 
of naive to memory cells.  While investigating  the in vitro 
propagation of RO + lymphocytes from TIL, we discovered 
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lymphocytes to convert to expression of RO  (18). This re- 
port  investigates  the  capacity for IL-2,  as  compared with 
other lymphotrophic cytokines, to promote highly enriched 
RA+/RO  -  PBL  to convert  to  expression of RA-/R.O* 
phenotype.  We also examine the effects of IL-2 on the ex- 
pression of adhesion molecules during the transition of purified 
RA +  T  cells  to  the RO +  phenotype.  Finally,  using  neu- 
tralizing anti-IL-2 antibody and cyclosporin A (CsA), we ex- 
amine the role of IL-2 as a mediator of memory conversion 
after stimulation of the TCR/CD3 complex. Our results sug- 
gest that IL-2 is a specific mediator involved in the conver- 
sion of naive T  cells to  the memory phenotype. 
Materials and Methods 
Study Design.  Highly purified RA+/RO -  peripheral blood 
lymphocytes were activated in vitro with either II.-2, IL-4, II.-6, 
IL-7, or with immobilized anti-CD3  mAb.  The effects of these 
different activating agents on the expression of CD45 isoforms, 
adhesion molecules and proliferation were sequentially evaluated 
after 4-21 d of culture. 
Media and Cytokines.  Complete medium (CM) was composed 
of RPMI  1640 (ICN Biomedicals,  Inc.,  Costa Mesa,  CA)  sup- 
plemented with  10% heat-inactivated filtered human AB serum 
(Irvine Scientific,  Santa  Ana,  CA),  0.01  M  Hepes  buffer,  and 
antibiotic-antimycotic mixture (Gibco Laboratories,  Grand Island, 
NY).  Recombinant  IL-2 (1.8  x  107  U/mg  protein)  was  the 
generous gift of Cetus Corp. (Berkeley, CA); recombinant IL-4 was 
obtained from Immunex Corp. (Seattle,  WA); recombinant Ib6 
was purchased from R & D Systems, Inc. (Minneapolis,  MN); and 
recombinant IL-7 was purchased from Sterling Drug, Inc. (Mal- 
vern, PA). CsA in a stock solution of 50 mg/ml was purchased 
from Sandoz Pharmaceuticals (East  Hanover, NJ). 
mAbs.  mAbs used for cell depletion and activation included 
preservative-free purified anti-CD45RA (Leu-18; Becton Dickinson 
& Co., Mountain View, CA), anti-CD45RO (UCHL1 clone; Dako 
Corp., Carpinteria, CA), and anti-CD3 (X35 clone; Amac, Inc., 
Westbrook, ME). Polyclonal rabbit anti-human IL-2 IgG (Collabora- 
tive Biomedical, Bedford, MA) with a neutralizing activity of 9.4 
IU//~g of antibody was used to block the effects of IL-2. FACS  | 
analysis was performed with the following panel of monoclonal 
antibodies: CD45RA-FITC (Leu-18), CD4-FITC, CD8-PE, CD56- 
PE,  and Leu-8-FITC (LAM-1)  from Becton Dickinson &  Co.; 
CD45RO-PE and CD45RO-FITC from Dako Corp.; CD5-FITC, 
CD11a-FITC, and CDw29-FITC from Amac, Inc.; and CD3-TC 
(Tri-Color  |  fluorochrome) and CD2-FITC from Caltag Laborato- 
ries (S. San Francisco,  CA). 
Isolation of RA +/RO- and RA -/RO* Lymphocytes from PBL. 
Peripheral  blood mononuclear cells from normal volunteers were 
isohted by Ficoll-Paque (Pharmacia LKB Biotechnology, Piscataway, 
NJ) density gradient centrifugation and depleted of monocytes by 
two rounds of plastic adherence, each for i h at 37~  The resulting 
nonadherent PBLs were enriched for cells expressing either the 
RA ~ or RO + isoform by labeling with isoform-specific  mAb (2 
/zg/10 6 cells) and negatively depleting with two rounds of goat 
anti-mouse immunoglobulin-conjugated magnetic beads (Dynal, 
Inc., Great Neck, NY) as previously described  (18). 
Activation with IL-2, IL4, IL6, and IL7.  To determine the di- 
rect effects of different cytokines on CD45 isoform expression,  we 
cultured RA +/RO-  lymphocytes at 106 cells/ml for up to 21 d 
in either various concentrations of 1I.-2, ranging from 20 to 500 
U/m1, or in 500 U/ml Ib4, 100 U/m1 Ib6, or 4,000 U/ml Ib7. 
Aliquots of these cell cultures were analyzed at different timepoints 
for the expression of CD45 isoforms, the expression of cell surface 
adhesion  molecules and for proliferation. RA-/RO + PBL were 
also cultured in 500 U/ml of II,-2 for comparison. 
Activation with Immobilized Anti-CD3.  To stimulate lympho- 
cytes via the TCR/CD3 complex we incubated 12-well microtiter 
plates overnight at 4~  with a 5-#g/ml solution of anti-CD3 mAb 
in PBS. Nonabsorbed anti-CD3 was washed out of the wells with 
PBS and RA§  -  lymphocytes were then cultured with the 
immobilized anti-CD3 and CM for 4 d  at  106 cells/ml (37~ 
These conditions maximally stimulate CD3 + lymphocytes (20). 
The role of 1I,-2 secretion  as  a mediator of anti-CD3-induced 
proliferation and CD45 isoform conversion was evaluated by adding 
either neutralizing anti-IL-2 antibody, CsA, or their combination, 
to duplicate culture wells at the beginning of the 4-d culture. Titra- 
tion experiments demonstrated that 200 #g/ml of anti-IL-2 anti- 
body was capable of completing neutralizing the effects of >500 
U/ml of Cetus IL-2 with respect to cell activation,  proliferation, 
and expression  of LAK activity. 
Proliferation Assay.  Lymphokine proliferation was assessed by 
the uptake of [3H]thymidine.  After various periods of incubation, 
105 viable lymphocytes from the different activation groups were 
placed in 96-well microtiter plates in triplicate.  Wells were pulsed 
with  1 #Ci of [3H]thymidine (Amersham International, Amer- 
sham,  UK) and incubated overnight in the presence of the indi- 
cated cytokines at 37~  Cells were then harvested on a PhD har- 
vester (Cambridge Technology, Inc., Cambridge,  MA), mixed with 
5 ml of scintillation cocktail (Research Products International Corp., 
Mt. Prospect, IL), and counted on a liquid scintillation  counter 
(Beckman Instruments Inc., Fullerton, CA). 
FACS|  Lymphocytes were labeled with fluorescently 
conjugated mAb specific for the various cell surface markers as de- 
scribed by the manufacturers. Cell surface phenotype was then de- 
termined by flow cytometry using a FACSCAN  |  II flow cytom- 
eter that was calibrated daily with "Calibrate beads" and Autocomp 
software (all from Becton Dickinson & Co.). 5,000-25,000 events 
were acquired for each sample using FACScan  |  Research software 
(Becton Dickinson & Co.) that simultaneously acquired data for 
forward-scatter, side-scatter,  fluorescence channel 1 (FITC label, 
FL1),  fluorescence  channel 2  (PE label,  FL2),  and  fluorescence 
channel 3 (TC label, FL3). The settings for all of these parameters 
were optimized at the initiation of the study and maintained con- 
stant during all analyses. Gates were set with respect tO the forward- 
and side-scatter  to exclude red blood cells and cell debris  and to 
include all other viable cell events. Individual sample data was ana- 
lyzed on a computer (9000 series model 310; Hewlett-Packard,  Palo 
Alto, CA) using the FACScan  |  Research  software.  This system 
allowed data to be regated with respect to two of the fluorescent 
markers (such as CD45RO-PE and CD3-TC) and analyzed with 
respect to a third fluorescent marker (such  as CDlla-FITC). 
Statistics.  Comparisons between  treatment  groups  was  per- 
formed with a paired Student's t test with a significant difference 
accepted as/) ~<0.05. Results presented as mean values  _+  SEM, 
unless  otherwise stated. 
Results 
IL-2 Promotes RA +/RO-  Lymphocytes to Express RO in 
Culture.  PBL from normal volunteers contained 53  _+ 2.9% 
RA*/RO-  cells,  15  _+  4.5%  RA§  + cells, and 31  _+ 
5.0%  RA-/RO  + cells  (n  =  4).  Negative selection using 
anti-CD45RO or anti-CD45RA mAb and immunomagnetic 
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CD56 +  /CD3 -  Lymphocytes 
Day 0*  Day 15 
Percent  CD3 +*  80.8  _+  4.0  70.6  +  4.9 
Percent CD56+/CD3 -  19.2  _+  4.0  30.4  _+  6.2 
*  RA+/RO -  PBLs were cultured in 500 U/ml of IL-2 for 0 or 15 d 
(n  =  5). 
t Relative percentage of lymphocytes expressing either the CD3 + or the 
CD3-/CD56 + phenotype as determined by two-color FACS  |  analysis. 
beads routinely produced a 97-99%  pure population of ei- 
ther RA +/R.O-  or RA-/RO  + lymphocytes, respectively. 
Viability was >90%. The RA-enriched population averaged 
80.8  +  4%  CD3 +  lymphocytes  and  19.2  +  4% 
CD3-/CD56 + cells (Table 1). The RO-enriched population 
contained only CD3 § lymphocytes. When cultured in CM 
containing IL-2 both the RA-enriched and RO-enriched popu- 
lations proliferated and maintained their viability for >3 wk. 
Sequential  FACS  |  analysis demonstrated  a stepwise conver- 
sion  of RA+/RO  -  cells from expression  of only the  RA 
isoform, to cells expressing both the RA and RO isoforms, 
and finally to cells exhibiting  only the RA-/RO  + pheno- 
type (Fig.  1; n  =  6).  In contrast,  purified RA-/RO  + PBL 
that  were  incubated  in  IL-2 maintained  their  RA-/RO  + 
phenotype  throughout  a  20-d  culture  period  (Fig.  2;  n  = 
3). Culture of RO + cells in IL-2 was associated with an in- 
crease in  their  size  (as measured by forward-scatter),  their 
intracellular complexity (as measured by side-scatter), and their 
autofluorescence (background fluorescent intensity). The ap- 
parent dim expression of CD45RA after 10 d of culture (Figs. 
1  and  2)  was  actually  due  to  this  increased  background 
autofluorescence  and  not  to  specific expression  of RA. 
The Kinetics and 11.-2 Dependence of  R O Expression Is Different 
for CD3 + and CD3- /CD56 + Lymphocytes.  The emergence 
of CD45RO  in response to titrating concentrations of IL-2 
was determined for the whole cell population and indepen- 
dently for the CD3 + and CD3-/CD56  + cell subsets (Fig. 
3).  The overall response  to IL-2 was concentration  depen- 
dent with an average of 74  _+  2.3%  of the cells converting 
to RO in response to 20 U/ml IL-2 (day 21) and 92  _+ 3.5% 
converting to RO in response to 500 U/ml of IL-2 (p <0.01, 
n  =  3). Analysis of the CD3 + subset demonstrated a similar 
IL-2-dependent  expression  of RO.  However,  the  response 
by CD3-/CD56 § cells was characteristically different. Max- 
imal expression of RO was observed with as little as 20 U/ml 
of IL-2. In addition,  the rate of conversion of CD3-/CD56 § 
cells to  the  RA-/RO  +  phenotype was  significantly  more 
rapid  than  that  observed  with  CD3 §  cells.  In  response 
to  500  U/ml  of  IL-2,  only  26  _+  5.4%  of CD3 +  cells 
expressed  RO  by day  7,  whereas  84  _+  4.0%  of CD3-/ 
CD56 + lymphocytes expressed RO  at the  same timepoint 
(Fig. 3; p  ~<0.01).  After 2 wk of culture the CD3-/CD56  + 
subset had expanded to account for ~-,30.4  _+ 6% of the total 
cell population  (Table  1). 
IL-4,  IL-6,  and  IL-7  Do  Not  Promote  the  Expression  of 
RO  The elaboration of lymphotrophic cytokines by RO § 
lymphocytes is postulated to be important in the activation 
of R.A § lymphocytes during  antigenic  stimulation.  To de- 
termine whether cytokines other than IL-2 promote the ex- 
pression of RO, we set up simultaneous cultures of purified 
RA +/RO-  PBL in high concentrations of either IL-2 (500 
U/ml),  IL-4 (500 U/ml),  IL-6 (100  U/ml),  or IL-7 (4,000 
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DAY 15  Figure  1.  IL-2  promotes RA +  / 
RO- lymphocytes to express RO 
in  culture.  RA +/RO-  PBL 
purified by negative selection were 
cultured in complete medium con- 
taining 500 U/ml I1--2  and analyzed 
on days 0, 5, 10, and 15 for inten- 
sity of staining with anti-CD45RA- 
FITC  (horizontal axis) and  anti- 
CD45RO-PE  (vertical axis) by 
FACS  |  analysis. A  stepwise con- 
version from expression of RA+/RO - , to expression of RA+/RO +  , to expression of the RA-/RO + phenotype was observed. The apparent low 
level expression of CD45RA on day 15 cells is due to the increased background autofluorescence of cultured cells and not to specific staining with 
anti-CD45RA.  Representative experiment, n  =  6. 
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Figure  2.  RA-/RO +  PBL  cultured  in  500 
U/ml of Ib2 maintain their phenotype for up to 
20 d in culture. Representative  experiment, n = 3. 
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Figure  3.  The kinetics and con- 
centration  dependence  of  11-2- 
induced expression of RO is differ- 
ent for CD3 + and CD3-/CD56 + 
lymphocytes.  RA+/RO -  PBL 
were cultured  in either 20  U/ml 
($),  100 U/ml (A), or 500 U/ml 
(m) of I1-2 for 21 d and analyzed 
by FACS  |  for the percentage oflym- 
phocytes expressing RO. Results are 
shown for the whole lymphocyte 
population  (A), and for the CD3 + 
subset  (B), and  for  the  CD3-/ 
CD56 + subset (C). Representative 
experiment,  n  =  3. 
was  essentially  restricted  to  those  cells  cultured  in  IL-2 
(n  =  2).  As shown in Fig. 4, 52% of cells cultured in IL-2 
for 10 d expressed the RA-/RO + phenotype, whereas only 
1, 3, or 6%  of cells cultured in IL-4, IL-6, or IL-7, respec- 
tively,  expressed  the  RA-/RO +  phenotype.  This  lack  of 
P,O expression was not a correlate of decreased cell viability, 
since viability remained  t>89%  in all of the  10-d cytokine 
cultures with the exception of IL-6 (92% for IL-2, 89% for 
IL-4,  90%  for IL-7,  and 56%  for IL-6). 
IL-2 Alters Adhesion  Molecule Expression  Only on Cultured 
RA +  /RO-  Lymphocytes  That Express  RO.  Characteristic 
patterns of adhesion molecule expression have been described 
for both  the  RA +  and  RO +  T  cell subpopulations  (5,  8, 
11),  as well as  for  IL-2  activated lymphocytes  (21).  Three- 
color FACS  |  analysis, which allowed selective gating on either 
CD3 +/RO  +  or CD3 +/P,O-  cells,  was  used  to  determine 
whether the alterations in adhesion molecule expression pro- 
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Figure  4.  IL-2  alone, but not IL-4, I1.6, or I1.7, promotes the expres- 
sion of RO. RA +/RO- PBLs were cultured  for 10 d in either 500 U/ml 
of Ib2 (A), 500 U/ml of Ib4 (B), 100 U/ml of 11.6 (C),  or 4,000 U/m1 
of 11.7 (D), and analyzed by FACS  |  for the expression of RA (horizontal 
axis) and  RO (vertical axis). Representative  experiment, n  =  2. 
duced by IL-2 occur equally in all T  cells,  or preferentially 
in those converting to expression of RO. Analyses were per- 
formed after  10 d  of IL-2 culture,  a time-point  at  which 
'060% ofT cells express RO and 40% still express only RA. 
As demonstrated in Fig. 5, freshly isolated RA +/RO-  lym- 
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Figure  5.  IL-2  alters adhesion  molecule  expression only on cultured 
RA+/RO -  lymphocytes  that express RO. KA+/RO -  PBL were cul- 
tured for 10 d in 500 U/ml of 11.2 and analyzed on days 0 and 10 with 
FITC-labeled mAbs for expression of the following adhesion molecules: 
CD2, CDlla, CDw29, and Leu-8. Histograms on the left show the results 
for day 10 cells that remained RA+/RO -  (RA --* R.A) and histograms 
on the right show  results for day 10 cells that developed expression of 
RO + (~  ~  P,O). 
860  Interleukin 2 Promotes  Peripheral Blood Lymphocytes to Express CD45RO iA  s c  llB   oc M,]c  I  A  i:iii:iii :: 
i  R1  =  2%  :  ,~'~..:  :  R1  =  .56%  , "  -'  R1  =  22%  o  i'"  :: 
.  ...... 
CD45RA  ....  > 
Figure 6.  1I.-2 is involved in the anti-CD3- 
induced expression of RO.  Fresh RA+IR.O - 
PBL (A) were cultured for 4 d in culture wells 
precoated with 5 #g/ml of anti-CD3 mAb (B), 
or in anti-CD3-coated  o.tlture  wells  containing  200 
/zg/ml of anti-IL-2 antibody (C). The effects of 
these treatments  on the expression  of  RA and RO 
and on [3H]thymidine  incorporation (in cpm) is 
shown for a representative  experiment (n  =  4). 
of the 32-integrin CD11a,  negligible levels of 3,-integrins 
as identified by CDw29, and high levels of the lymph node 
high endothelial venule ligand, LAM-1 (Leu-8). Cells that 
remained KA +/RO-  after 10 d of culture demonstrated no 
change from this baseline adhesion molecule profile. In con- 
trast,  T  cells  that  developed expression of RO +  demon- 
strated a marked increase in their expression of CD2, CD11a, 
and CDw29, and a decrease in their expression of  Leu-8. This 
latter adhesion molecule profile is similar to that observed 
on fresh and IL-2 activated R.A-/RO + lymphocytes. 
IL-2 Is a  Mediator in  the Anti-CD3-induced Expression  of 
RO.  Since exposure to IL-2 alone promoted lymphocytes 
to express RO, we used neutralizing anti-IL-2 antibody and/or 
CsA to determine the role of IL-2 as a mediator of RO ex- 
pression after cross-linking of the CD3 receptor. As demon- 
strated in Fig.  6,  stimulation of RA +/KO-  lymphocytes 
with immobilized anti-CD3 produced a rapid expression of 
KO by day 4 of culture. The addition of 200/zg/ml of anti- 
IL-2 antibody to these cultures, a concentration sufficient to 
completely neutralize the effects of >500 U/ml of exogenous 
IL-2, significantly reduced the number and intensity of cells 
expressing RO (44 _+  10.4% reduction in RO, n  =  4). The 
effect of anti-IL-2 antibody on proliferation was more vari- 
able,  ranging from 0.0 to 56%  suppression. Similar to the 
effects of anti-IL-2, CsA at 5 #g/ml significantly reduced the 
anti-CD3-stimulated expression of RO (38.4 +  3.5% reduc- 
tion, n =  3) and this effect was only slightly more pronounced 
when CsA,  anti-IL-2, and anti-CD25  antibody were used 
in combination (Table 2). CsA blocks several early activation 
genes including IL-2, IL-4, and IFN-3, (22, 23). To confirm 
the role of IL-2 in CsA-mediated inhibition we therefore simul- 
taneously added 500 U/ml of exogenous IL-2 to some of the 
CsA-treated cultures. Exogenous IL-2 restored RO expres- 
sion to a level indistinguishable from that expressed by con- 
trol anti-CD3 stimulated cells (89  _+  1% vs. 92 _+  1%, respec- 
tively; Table 2). These results suggest that endogenous IL-2 
production plays a significant role in the expression of RO 
after cross-linking of the CD3 receptor. 
Discussion 
While the exact functions of the different CD45 isoforms 
remain to be determined, these molecules appear to modu- 
late lymphocyte activation, effector  function, and signal trans- 
duction in a variety of cell types ranging from NK cells (24, 
25), to B cells (25, 26), to T cells (27, 28). In T cells, CD45 
molecules may complex with CD2 and/or CD3 and their 
protein tyrosine phosphatase activity may modulate signal 
transduction via these molecules (29-31). Regardless of their 
exact function, specific expression of the RA and RO iso- 
Table  2.  Role of IL-2 in Anti-CD3-stimulated  Expression of CD45RO 
Exp.  1 
Treatment  Percent R.O +  Proliferation 
Exp.  2  Exp.  3 
Percent RO §  Proliferation  Percent RO §  Proliferation 
~m 
Anti-CD3 only*  93  24,493  _+  1,504  93 
Anti-CD3  +  CsA*  59  3,981  _+  101  60 
Anti-CD3  +  CsA 
+  anti-IL-2/anti-CD-25 s  43  3,474  _+  130  53 
anti-CD3  +  CsA  +  IL-211  nd  nd  90 
cpm  cpm 
23,753  _+  779  90  16,660  _+  1,357 
1,595  _+  666  51  2,215  _+  112 
583  -+  151  35  3,149  -+  272 
20,719  _+  1,330  88  24,715  _+  383 
* RA +/RO-  PBL cultured for 4 d with 5 #g/ml immobilized anti-CD3 and evaluated for KO expression (FACS  |  analysis) and proliferation 
([3H]thymidine uptake). 
RA+/RO-  PBL cultured with anti-CD3 and 5 #g/ml CsA. 
S KA +/KO-  PBL cultured with anti-CD3, 5 #g/ml CsA, 200 #g/ml anti-IL-2, and 20 #g/ml anti-CD25. 
II RA+/RO-  PBL cultured with anti-CD3, 5 /~g/ml CsA, and 500 U/ml Cetus IL-2. 
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tifying naive and memory populations, respectively.  Cells ex- 
pressing  the  R.A-/R.O  +  phenotype,  whether  purified 
directly from peripheral  blood or induced by activation of 
the TCR/CD3 complex, are distinguished from naive T cells 
by their expression of activation markers,  by their elabora- 
tion of cytokines, by specific  alterations in their expression 
of adhesion  molecules,  and by their capacity to provide T 
cell help and to respond rapidly and specifically to a secondary 
antigen  challenge  (4-13). 
Antigen presentation is believed to be the primary in situ 
signal responsible for transition  from the naive  to memory 
state and can be mimicked in vitro by stimulating the TCR/ 
CD3 complex with either alloantigens or nonspecific mitogens 
such as Con A, PHA, or anti-CD3 mAb (10, 13, 20). While 
it is readily appreciated that such stimulation induces RA  + 
ceils to secrete primarily IL-2 (8, 9, 20, 32), little has been 
previously reported about the role of this or other cytokines 
in the conversion from RA to RO. DeJong et al. (20) reported 
that exogenous IL-2 augments the proliferation of both resting 
and anti-CD3  activated RA + T  cells,  but that  anti-CD25 
mAb does not reduce proliferation if these cells are optimally 
stimulated with immobilized anti-CD3.  They imply from 
these results that both IL-2-dependent and IL-2-independent 
proliferation  occurs when  P..A + cells  are stimulated at  the 
TCR/CD3 complex. Wasik and Morimoto (33) observed that 
IL-2, IL-4, and IL-6, either alone or in combination, augment 
anti-CD3-induced proliferation of RA §  § T cells. Nei- 
ther study examined the effects of these cytokine manipulations 
on RO + expression or memory-like function. Braakman et 
al.  (34) were the first to suggest  that  stimulation  by IL-2 
might be directly involved in the expression of RO.  They 
described the development of RO on a percentage of NK 
cells and 7/c5 T  cells that  were cultured for 1 wk in IL-2, 
but this effect was not well delineated. While examining the 
effects of IL-2 culture on TIL, we observed a progressive en- 
richment of the R.A-/RO + population (18). To evaluate this 
further,  we cultured purified RA +/RO-  PBL in IL-2 and 
observed their stepwise conversion  to the RA-/RO § pheno- 
type over 1-3 wk in culture. In this report, we confirm that 
IL-2 alone, in the absence of antigens or mitogens, induces 
R.A + lymphocytes to switch to expression of RO. IL-2 also 
maintained  the expression of RO on purified RA-/RO + 
PBL that were cultured in vitro for up to 3 wk. Conversion 
of RA + cultures to expression of RO cannot be explained 
by simple expansion  of contaminating  RO + lymphocytes. 
Not only did our R_A + population routinely contain <1% 
RA-/R.O  + cells, but the pattern of expression was a step- 
wise conversion from RA+/RO - , to RA+/RO +,  and fi- 
nally to RA-/RO +.  In  addition,  we and others  (32,  35) 
have not observed any significant growth advantage of the 
RO population,  over the RA + population,  when cultured 
in IL-2. A negative depletion technique was used in this study 
in order to avoid direct activation of the cells being studied 
(36),  and a two-phase adherence was performed to remove 
monocytes and dendritic  cells  that  might  have induced  an 
autologous MLR.  In some studies we also used autologous 
serum to control for nonspecific TCR activation. No differ- 
ence was observed between autologous and allogeneic serum. 
The efficacy of all  of these precautions is born out by the 
fact that only cultures containing IL-2 progressed to expres- 
sion of RO. 
IL-2-induced  transition  to  the  RA-/R.O +  phenotype 
was observed for both  the  CD3 §  and  CD3-/C56 §  sub- 
populations, but with different kinetics and dose responses 
for  each  subgroup.  CD3 §  cells  converted  in  a  step-wise 
and concentration-dependent  manner,  while CD3-/CD56 § 
lymphocytes  rapidly  and  maximally  converted  to  the 
RA-/RO + phenotype in response to as little as 20 U/ml 
of IL-2. Essentially all circulating  CD3-/CD56 § lympho- 
cytes express the RA +/RO-  phenotype and function as NK 
cells (34).  Their culture in IL-2 is not only associated with 
the rapid expression of RO, but also with the rapid upregu- 
lation of adhesion molecules, enhanced cytokine secretion, 
and induction of LAK activity (21). These functional altera- 
tions are remarkably  similar  to those described for T  cells 
converting to the memory state.  The fact that  IL-2 induces 
both  CD3 +  and  CD3-/CD56 +  lymphocytes  to  express 
R.O, even though CD3-/CD56 § cells lack a TCR, supports 
our hypothesis that  IL-2 is directly involved in the process 
of CD45  isoform conversion. 
The expanded cytokine production of RO § lymphocytes, 
and the apparent role of these cytokines in promoting T cell 
growth and activity, has been taken to suggest a synergistic 
interaction  between naive and memory T  cells during im- 
mune responses (5, 7).  We therefore examined if cytokines 
other than  IL-2 might  similarly promote cultured cells  to 
express RO. However, while IL-4, IL-6, and IL-7 maintained, 
or even promoted cell growth in culture, we did not observe 
any significant expression of RO in response to any of these 
cytokines. Since Wasik and Morimoto (33) report that IL-4 
and IL-6 augment proliferation of RA + T cells when added 
to IL-2, it is possible that combinations of these cytokines 
might augment maturation  to a memory cell state;  we did 
not specifically test for such a response in this study. Alterna- 
tively, Brod et al.  (37) observed that  IL-6 upregulates  RA 
expression in some RO + T cell clones and it is possible that 
some cytokines may promote expression of RA rather than 
RO. 
As another measure of lymphocyte maturation we correlated 
the changes in RA and RO expression during culture to the 
effects of IL-2 on adhesion molecule expression.  RA + and 
R.O + T  cells typically express different adhesion  molecule 
profiles (5, 6, 11). R.A + lymphocytes do not express 31 inte- 
grins,  whereas  RO +  cells  do;  RA +  lymphocytes express 
moderate levels of 32 integrins,  whereas RO + lymphocytes 
express  high  levels;  and  RA +  lymphocytes  express  high 
levels of the LAM-1, whereas populations of RO + lympho- 
cytes lose expression of this high endothelial venule ligand. 
This differential expression of adhesion molecules by naive 
and memory T  cells is believed to be intimately related to 
their different trafficking and effector functions  (5,  6).  We 
hypothesized that IL-2-induced alterations in adhesion mol- 
ecule expression,  which are known to occur when  T  cells 
are cultured in IL-2 (21), might be restricted to those T cells 
converting  to  expression  of  RO.  This  hypothesis  was 
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at which only 50-60%  of the cells express RO. Enhanced 
expression  of CD2, CDlla, and CDw29, and a decrease in 
expression  of LAM-1,  was  observed  only  in  the  RO + 
subset.  These results suggest that IL-2 not only promotes 
the expression of CD45RO, but that it is responsible for the 
phenotypic profile of memory T  cells. 
Stimulation of the TCR/CD3 complex is the primary in 
vivo signal that results in T  cell activation and the acquisi- 
tion of memory during an immune response. To examine the 
role of endogenous IL-2 during T  cell activation we stimu- 
lated RA+/RO -  lymphocytes with immobilized anti-CD3 
mAb in the presence or absence of neutralizing antibody to 
IL-2. Similar to the report by de Jong et al. (20),  anti-IL-2 
antibody had a variable effect on proliferation with no sup- 
pression in several cases. In contrast, anti-IL-2 antibody uni- 
formly suppressed  (but did not eliminate) the number and 
intensity of cells expressing RO. To confirm these findings 
we also stimulated RA +/RO- lymphocytes in the presence 
of either CsA or a mixture of CsA and anti-IL-2 and anti- 
CD25 antibodies. CsA reduced the acquisition of RO to a 
level similar to that produced by anti-IL-2, and the combina- 
tion reduced the expression of RO slightly better than either 
agent alone. CsA exerts its effects by blocking the activation 
of several genes including those coding for IL-2, IL-4, and 
IFN-3' (22,  23).  We therefore examined the specific role of 
IL-2 by supplementing CsA-treated cultures with exogenous 
IL-2. As hypothesized, exogenous IL-2 abrogated the effects 
of CsA and completely restored both proliferation and RO 
expression.  The implications of these studies are that IL-2 
plays a direct role in mediating RO expression, that IL-2 may 
further augment RO expression through its effects on prolifer- 
ation, and that factors other than IL-2 must also be involved 
in promoting RO expression since stimulation with anti-CD3 
produced RO + cells even in the presence of CsA, anti-IL-2, 
and anti-CD25. The exact nature, role and interaction of these 
other signals  remain to be elucidated. 
In summary, IL-2 promotes highly purified RA +/RO- 
lymphocytes to  convert to  the  RA-/RO + phenotype in 
vitro. This conversion occurs  for both the CD3 § and the 
CD3-/CD56 + subsets and is associated with the acquisition 
of an adhesion molecule profile identical to that found on 
classic memory cells. Blocking experiments with anti-IL-2 
and CsA likewise suggest that endogenous production of IL-2 
is one of the factors mediating RO expression  when T cells 
are stimulated via the TCR/CD3 complex. CD45RO ex- 
pression,  especially in cultured lymphocytes, may not always 
indicate prior antigenic exposure. 
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